Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Family history ups risk of second cancers, death in men with prostate cancer

11 Sep 2018
Prostate cancer is a silent killer. Many may not be aware of the illness until it is too late.

One crucial cause of death in patients with prostate cancer is second primary cancer (SPC), and an essential risk factor for SPCs is family history, a recent study has found.

A total of 6,396 men were diagnosed with SPC, of whom more than a third had first-degree family history of any cancer. Familial risk was 1.37 (95 percent CI, 1.271.40) vs 1.10 (1.08–1.16) for those without a family history.

By 83 years of age, cumulative incidence reached 21 percent for prostate cancer alone, 28 percent in patients with SPC and 35 percent in those with both SPC and family history. An association existed between family history and the risk of seven specific SPCs (colorectal, lung, kidney, bladder, melanoma and squamous cancers, and leukaemia).

Common SPCs included colorectal and lung cancers, and the risk of such SPCs doubled in patients with family history. SPC was the cause of half of deaths in patients with SPC, and only 12.77 percent were caused by prostate cancer. Lung and colorectal cancers were the most common causes of deaths in SPC.

“Prevention of SPC should be essential when prostate cancer survival rates are being improved, and this could start by conducting a thorough assessment of family history at the time of prostate cancer diagnosis,” researchers said.

A nationwide cohort study was conducted based on the Swedish Family-Cancer Database covering 4.4 million men and 80,449 prostate cancers diagnosed between 1990 and 2015. Researchers calculated relative risks and cumulative incidence for SPCs and for familial SPC for prostate cancer patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.